Hjem › Akut bifenoypisk leukemi
Kliniske studier for Akut bifenoypisk leukemi rekrutterer i USA
37 studier for Akut bifenoypisk leukemi rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Seattle, WA15 studier
- Houston, TX11 studier
- New York City, NY10 studier
- Atlanta, GA9 studier
- Durham, NC8 studier
- Memphis, TN7 studier
- Chicago, IL7 studier
- Charlotte, NC6 studier
- Aurora, CO6 studier
- Baldwin Park, CA6 studier
- Los Angeles, CA6 studier
- Portland, OR6 studier
- Philadelphia, PA6 studier
- Dallas, TX6 studier
- San Diego, CA5 studier
- Boston, MA5 studier
- San Francisco, CA5 studier
- Tampa, FL5 studier
- Clifton, NJ5 studier
- Greenburgh, NY5 studier
- Columbus, OH5 studier
- Nashville, TN5 studier
- Fort Worth, TX5 studier
- Cincinnati, OH5 studier
- Minneapolis, MN5 studier
- Mountain View, CA4 studier
- Jacksonville, FL4 studier
- Denver, CO4 studier
- Milwaukee, WI4 studier
- Greenville, NC4 studier
- St. Louis, MO4 studier
- Kansas City, MO4 studier
- Akron, OH4 studier
- Baltimore, MD4 studier
- Cleveland, OH4 studier
- Gainesville, FL4 studier
- Orange, CA4 studier
- Queens, NY4 studier
- Edison, NJ4 studier
- Washington, DC4 studier
Etter delstat
- Alabama3 studier
- Alaska3 studier
- Arizona3 studier
- Arkansas3 studier
- California15 studier
- Colorado8 studier
- Connecticut3 studier
- Delaware3 studier
- District of Columbia4 studier
- Florida9 studier
- Georgia9 studier
- Hawaii3 studier
- Idaho3 studier
- Illinois7 studier
- Indiana4 studier
- Iowa4 studier
- Kentucky4 studier
- Louisiana4 studier
- Maine3 studier
- Maryland4 studier
- Massachusetts5 studier
- Michigan4 studier
- Minnesota6 studier
- Mississippi3 studier
- Missouri5 studier
- Nebraska4 studier
- Nevada3 studier
- New Hampshire3 studier
- New Jersey6 studier
- New York11 studier
- North Carolina11 studier
- North Dakota3 studier
- Ohio8 studier
- Oklahoma5 studier
- Oregon6 studier
- Pennsylvania6 studier
- Rhode Island3 studier
- South Carolina3 studier
- South Dakota3 studier
- Tennessee10 studier
- Texas13 studier
- Utah3 studier
- Virginia3 studier
- Washington15 studier
- West Virginia3 studier
- Wisconsin5 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RekruttererFase 1
Alder 12 til 78 · Alle kjønn · Oppdatert 29. sep. 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekruttererFase 2
365 Days · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06317662CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04375631Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07094750A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RekruttererFase 1/2
30 Days · Alle kjønn · Oppdatert 16. sep. 2026 · NCT04065399Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT03683433Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
RekruttererFase 1/2Frivillige helsepersonell ønskes velkommen
Opp til 50 år · Alle kjønn · Oppdatert 1. sep. 2026 · NCT05322850Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekruttererFase 3
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruttererFase 1/2
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
RekruttererFase 2
Alder 1 til 18 · Alle kjønn · Oppdatert 10. aug. 2026 · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
RekruttererFase 1
Alder 1 til 30 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06177067Personalized NK Cell Therapy in CBT
RekruttererFase 2
Alder 15 til 80 · Alle kjønn · Oppdatert 30. jul. 2026 · NCT02727803Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RekruttererFase 2
6 Months – 65 Years · Alle kjønn · Oppdatert 22. jul. 2026 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 20. jul. 2026 · NCT07046078Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
RekruttererFase 4
Alder 1 til 18 · Alle kjønn · Oppdatert 14. jul. 2026 · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jul. 2026 · NCT07216443Allo HSCT Using RIC and PTCy for Hematological Diseases
RekruttererFase 2
Opp til 75 år · Alle kjønn · Oppdatert 6. jul. 2026 · NCT05805605Registry of Older Patients With Cancer
RekruttererObservasjonsstudie
Alder 65 og eldre · Alle kjønn · Oppdatert 29. jun. 2026 · NCT01137825Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
RekruttererFase 1
Alder 18 til 70 · Alle kjønn · Oppdatert 23. jun. 2026 · NCT06551584211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RekruttererFase 1/2
Alder 18 til 75 · Alle kjønn · Oppdatert 22. jun. 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RekruttererFase 1/2
Alder 18 til 75 · Alle kjønn · Oppdatert 22. jun. 2026 · NCT03670966A Study of Revumenib and Mezigdomide in People With Leukemia
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 22. jun. 2026 · NCT07356154Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jun. 2026 · NCT04047641Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RekruttererFase 2Frivillige helsepersonell ønskes velkommen
6 Months · Alle kjønn · Oppdatert 29. mai 2026 · NCT04195633Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.